Showing 1-4 of 4

Sorted By:

  • Lung (Non-Small Cell) Cancer: A081105

    The purpose of this study is to compare any good and bad effects patients with early stage non-small cell lung cancer that was surgically removed may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).

  • Lung (Non-Small Cell) Cancer: A151216

    The purpose of this research study is to look at lung cancer patients’ tumors that were removed by surgery for certain genetic changes, and to possibly offer these patients a treatment study with drugs that may specifically target tumors that have these genetic changes.

  • Lung (Non-Small Cell) Cancer: E4512 (Iowa Cancer Specialists)

    The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for patients with ALK-positive non-small cell lung cancer.

  • Lung Cancer: EA5142

    The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer.

Page InfoPage
Showing trials 1-4 of 4

View Additional Section Content

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email